Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
NCT07287033
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Peanut Allergies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 12 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mabylon AG
- Last updated on ClinicalTrials.gov
- August 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 2
- Children's Hospital Colorado · Aurora, CO
- Asthma and Allergy Associates, PC · Colorado Springs, CO
Florida · 1
- University of South Florida · Tampa, FL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- Mary H. Weiser Food Allergy Center (MHWFAC) University of Michigan - Michigan Medicine · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.